Jupiter Full Face Mask
DeviceFull Face Mask for the treatment of obstructive sleep apnea (OSA) using CPAP therapy.
NCT Number: NCT02938208
This investigation is a prospective non-blinded and non-randomized clinical investigation. This investigation is designed to evaluate the performance (leak and comfort) as well as participant's overall acceptance of the Jupiter mask amongst OSA participants. A total number of up to 15 OSA participants who currently use full face masks will be recruited for the trial.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Fisher & Paykel Healthcare, Auckland, New Zealand
This investigation is designed to evaluate the performance (leak and comfort) as well as participant's overall acceptance of the Jupiter mask amongst OSA participants. A total number of up to 15 OSA participants who currently use full face masks will be recruited for the trial. The participants will be recruited from the Fisher and Paykel Healthcare Database of subjects with OSA (Ethics reference NTY/08/06/064), Auckland District Health Board (ADHB), or WellSleep Centre (Bowen Hospital, Wellington, NZ).
Participants will be on the trial for 21 days ± 6 days, using the prototypes at home for 14 days ± 3 days. PAP baseline data on the participant's prescribed treatment pressure with their usual mask and will be collected for 7 days ± 3 days prior to mask fitting with the Jupiter trial mask.
Fisher and Paykel Healthcare will act as the investigator and sponsor for this investigation. This study will be conducted in accordance with ICH/GCP Guidelines. No deviation from the protocol will be implemented without prior review and approval of the sponsor except where it may be necessary to eliminate an immediate hazard to a research participant. In such case, the deviation will be reported to the sponsor (Bhavi Ogra) as soon as possible.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Full Face Mask for the treatment of obstructive sleep apnea (OSA) using CPAP therapy.
Time frame: Up to 21 ± 6 days in-home
Obtained from participant's CPAP device, measured in L/min
Time frame: Up to 21 ± 6 days in-home
Subjective Questionnaire
Time frame: Up to 21 ± 6 days in-home
Subjective Questionnaire
Time frame: Up to 21 ± 6 days in-home
Subjective Questionnaire
Time frame: Up to 21 ± 6 days in-home
Subjective Questionnaire
Time frame: Up to 21 ± 6 days in-home
Subjective Questionnaire
Time frame: Up to 21 ± 6 days in-home
Subjective Questionnaire
Time frame: Up to 21 ± 6 days in-home
Usability activity during visit 2 with subjective questionnaire after activity
Fisher and Paykel Healthcare
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03964376
Apnea, Dyssomnias
Toronto, Ontario, Canada
View Trial DetailsNCT03718858
Apnea, Dyssomnias
Toronto, ON Ontario, Canada
View Trial DetailsNCT01918007
Apnea, Dyssomnias
Athens, Greece
View Trial DetailsNCT03226652
Apnea, Cardiovascular Diseases
London, United Kingdom
View Trial Details